title: Mucosal and systemic adjuvant activity of alphavirus replicon particles.
abstract: Vaccination represents the most effective control measure in the fight against infectious diseases. Local mucosal immune responses are critical for protection from, and resolution of, infection by numerous mucosal pathogens. Antigen processing across mucosal surfaces is the natural route by which mucosal immunity is generated, as peripheral antigen delivery typically fails to induce mucosal immune responses. However, we demonstrate in this article that mucosal immune responses are evident at multiple mucosal surfaces after parenteral delivery of Venezuelan equine encephalitis virus replicon particles (VRP). Moreover, coinoculation of null VRP (not expressing any transgene) with inactivated influenza virions, or ovalbumin, resulted in a significant increase in antigen-specific systemic IgG and fecal IgA antibodies, compared with antigen alone. Pretreatment of VRP with UV light largely abrogated this adjuvant effect. These results demonstrate that alphavirus replicon particles possess intrinsic systemic and mucosal adjuvant activity and suggest that VRP RNA replication is the trigger for this activity. We feel that these observations and the continued experimentation they stimulate will ultimately define the specific components of an alternative pathway for the induction of mucosal immunity, and if the activity is evident in humans, will enable new possibilities for safe and inexpensive subunit and inactivated vaccines.
authors.affiliation: Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA.
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Thompson
authors.forename: Alan C
authors.initials: AC
authors.lastname: Whitmore
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Konopka
authors.forename: Martha L
authors.initials: ML
authors.lastname: Collier
authors.forename: Erin M B
authors.initials: EM
authors.lastname: Richmond
authors.forename: Nancy L
authors.initials: NL
authors.lastname: Davis
authors.forename: Herman F
authors.initials: HF
authors.lastname: Staats
authors.forename: Robert E
authors.initials: RE
authors.lastname: Johnston
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D002772:Cholera Toxin / Q000008:administration & dosage / Q000276:immunology; D004666:Encephalitis Virus, Venezuelan Equine / Q000276:immunology*; D005260:Female; D018928:Immunity, Mucosal; D007114:Immunization; D007070:Immunoglobulin A / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage / Q000276:immunology; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D012093:Replicon / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D009838:Oligodeoxyribonucleotides; D010047:Ovalbumin; D002772:Cholera Toxin